Research programme: antibody-based cancer therapies - Amgen/Oxford BioTherapeutics

Drug Profile

Research programme: antibody-based cancer therapies - Amgen/Oxford BioTherapeutics

Alternative Names: OX 076

Latest Information Update: 09 May 2014

Price : $50

At a glance

  • Originator Amgen; Oxford Genome Sciences
  • Developer Amgen; Oxford BioTherapeutics
  • Class Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Cancer

Most Recent Events

  • 07 May 2014 Preclinical trials in Breast cancer in United Kingdom (Parenteral)
  • 06 Apr 2010 Preclinical development is ongoing in United Kingdom
  • 17 Dec 2007 Preclinical trials in Cancer in United Kingdom (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top